CRIS Current Research Information System

GAMBINERI, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.468
EU - Europa 3.733
AS - Asia 1.803
AF - Africa 227
SA - Sud America 28
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 4
Totale 11.276
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.451
GB - Regno Unito 932
IT - Italia 778
CN - Cina 670
DE - Germania 489
SG - Singapore 472
SE - Svezia 457
VN - Vietnam 307
IN - India 253
RU - Federazione Russa 190
UA - Ucraina 183
IE - Irlanda 175
FR - Francia 150
TG - Togo 83
ZA - Sudafrica 82
CH - Svizzera 78
EE - Estonia 66
BG - Bulgaria 58
FI - Finlandia 38
NL - Olanda 36
AT - Austria 27
CI - Costa d'Avorio 27
NG - Nigeria 22
ID - Indonesia 17
JO - Giordania 16
BE - Belgio 14
BR - Brasile 14
CA - Canada 12
AL - Albania 11
AU - Australia 11
IR - Iran 11
SC - Seychelles 11
JP - Giappone 10
GR - Grecia 9
PH - Filippine 9
HR - Croazia 7
RO - Romania 7
DK - Danimarca 6
HK - Hong Kong 6
BD - Bangladesh 5
NO - Norvegia 5
PE - Perù 5
CL - Cile 4
ES - Italia 4
EU - Europa 4
LB - Libano 4
TW - Taiwan 4
AR - Argentina 3
KR - Corea 3
KZ - Kazakistan 3
MD - Moldavia 3
PT - Portogallo 3
TR - Turchia 3
BA - Bosnia-Erzegovina 2
HN - Honduras 2
HU - Ungheria 2
IL - Israele 2
NZ - Nuova Zelanda 2
PK - Pakistan 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
BO - Bolivia 1
BZ - Belize 1
EG - Egitto 1
FK - Isole Falkland (Malvinas) 1
JM - Giamaica 1
KE - Kenya 1
LA - Repubblica Popolare Democratica del Laos 1
MX - Messico 1
MY - Malesia 1
PL - Polonia 1
QA - Qatar 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 11.276
Salva come PNG Salva come JPEG
Città #
Southend 835
Fairfield 740
Singapore 427
Chandler 406
Ashburn 382
Woodbridge 368
Seattle 328
Houston 321
Wilmington 318
Santa Clara 273
Bologna 262
Princeton 231
Dong Ket 225
Ann Arbor 217
Cambridge 209
Dublin 175
Boardman 143
Jacksonville 117
Westminster 98
Nanjing 92
Lomé 83
Padova 83
Berlin 75
Bern 59
Sofia 58
Saint Petersburg 54
San Diego 44
Beijing 43
Shenyang 41
Jinan 40
Redwood City 39
Helsinki 38
Milan 36
Hebei 35
Redmond 35
Bremen 33
New York 32
Changsha 29
Guangzhou 29
Mülheim 29
Abidjan 27
Nanchang 25
Norwalk 25
Turin 25
Tianjin 24
Vienna 24
Abeokuta 22
Dearborn 22
Falls Church 22
Des Moines 20
Hyderabad 19
Los Angeles 19
Olalla 19
Zhengzhou 18
Amman 16
Jakarta 16
Jiaxing 15
Rome 15
Wuhan 14
Brussels 13
Florence 13
Haikou 13
Shanghai 13
Medford 12
Ningbo 12
Taizhou 12
Vicenza 12
Amsterdam 11
Dronten 10
Mahé 10
Durrës 9
Lanzhou 9
San Venanzo 9
Boydton 8
Geneva 8
Hangzhou 8
Kansas City 8
São Paulo 8
Taiyuan 8
Frankfurt am Main 7
London 7
Modena 7
Phoenix 7
Shenzhen 7
Buffalo 6
Foshan 6
Paris 6
San Jose 6
Tokyo 6
Verona 6
Bühl 5
Cagliari 5
Cento 5
Cesena 5
Costa Mesa 5
Frankfurt Am Main 5
Kuban 5
Kunming 5
Lima 5
Toronto 5
Totale 7.796
Salva come PNG Salva come JPEG
Nome #
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial 247
Defining hyperandrogenism in women with polycystic ovary syndrome: A challenging perspective 200
Body mass index rather than the phenotype impacts precocious ultrasound cardiovascular risk markers in polycystic ovary syndrome 199
17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome. 182
Behavioral, socio-environmental, educational and demographic correlates of excess body weight in Italian adolescents and young adults 180
Androgen Profiling by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) in Healthy Normal-Weight Ovulatory and Anovulatory Late Adolescent and Young Women 169
A combination of polymorphisms in HSD11B1 associates with in vivo 11{beta}-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome. 164
A new interaction to come: Ghrelin and steroid hormones 161
Altered adipocyte differentiation and unbalanced autophagy in type 2 Familial Partial Lipodystrophy: an in vitro and in vivo study of adipose tissue browning 157
Sex hormones, obesity and type 2 diabetes: is there a link? 151
Plasma 2-arachidonoylglycerol is a biomarker of age and menopause related insulin resistance and dyslipidemia in lean but not in obese men and women 147
New insights on diabetes in Turner syndrome: results from an observational study in adulthood 144
Anti-müllerian hormone and insulin-like 3 levels in healthy normal-weight ovulatory and anovulatory eumenorrheic late adolescent females: potential early biomarkers of ovarian dysfunction? 143
Dietary habits and their relationship with hormones and metabolism in overweight and obese women with polycystic ovary syndrome 131
Profiling plasma N-Acylethanolamine levels and their ratios as a biomarker of obesity and dysmetabolism 129
Insulin sensitizers in polycystic ovary syndrome 128
Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. 127
Short-term modification of sex hormones is associated with changes in ghrelin circulating levels in healthy normal-weight men. 124
The empowerment of translational research: lessons from laminopathies. 123
Clinical assessment of allostatic overload in adolescent and young women with hyperandrogenic states 123
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. 123
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. 120
Common variants in the sex hormone-binding globulin gene (SHBG) and polycystic ovary syndrome (PCOS) in Mediterranean women. 120
Psychological aspects of hyperandrogenic states in late adolescent and young women. 117
Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study. 116
The Steroid Profile of Adrenal Incidentalomas: Subtyping Subjects With High Cardiovascular Risk 116
Ghrelin and reproductive disorders. 115
In memoriam: Renato Pasquali (1946-2019) 115
A comprehensive approach in diagnosing the polycystic ovary syndrome 114
Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. 112
Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors 112
Salivary cortisol and cortisone responses to short-term psychological stress challenge in late adolescent and young women with different hyperandrogenic states 112
Steroid biomarkers for identifying non-classic adrenal hyperplasia due to 21-hydroxylase deficiency in a population of PCOS with suspicious levels of 17OH-progesterone 112
Female and male serum reference intervals for challenging sex and precursor steroids by liquid chromatography - tandem mass spectrometry 112
Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome. 111
Impact of age, body weight and metabolic risk factors on steroid reference intervals in men 111
Metabolic effects of obesity on reproduction. 110
Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin 109
Estimation of reference intervals of five endocannabinoids and endocannabinoid related compounds in human plasma by two dimensional-LC/MS/MS 108
Maternal polycystic ovary syndrome may be associated with adverse pregnancy outcomes. 108
Serum steroid profiling by isotopic dilution-liquid chromatography-mass spectrometry: comparison with current immunoassays and reference intervals in healthy adults. 108
Revisiting hyper- and hypo-androgenism by tandem mass spectrometry. 107
Targeting insulin sensitivity in the treatment of polycystic ovary syndrome 107
Familial partial lipodystrophy, mandibuloacral dysplasia and restrictive dermopathy feature barrier-to-autointegration factor (BAF) nuclear redistribution 107
Obituary: Renato Pasquali (1946-2019) 106
Parallel variations of insulin-like peptide 3 (INSL3) and antimüllerian hormone (AMH) in women with the polycystic ovary syndrome according to menstrual cycle pattern. 105
Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study. 105
No metabolic impact of surgical normalization of hyperandrogenism in postmenopausal women with ovarian androgen-secreting tumours 105
An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence. 104
Basal insulin-like factor 3 levels predict functional ovarian hyperandrogenism in the polycystic ovary syndrome. 104
Androgens and Severe Insulin Resistance States: Basic and Clinical Aspects 104
Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome. 103
Prominent role of low HDL-cholesterol in explaining the high prevalence of the metabolic syndrome in polycystic ovary syndrome. 103
Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects 103
Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome. 102
Prevalence and Incidence of Atrial Fibrillation in a Large Cohort of Adrenal Incidentalomas: A Long-Term Study 102
Tissue-specific dysregulation of 11β-hydroxysteroid dehydrogenase type 1 in overweight/obese women with polycystic ovary syndrome compared with weight-matched controls 101
Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome. 100
Role of changes in dietary habits in polycystic ovary syndrome. 100
Sex-dependent role of glucocorticoids and androgens in the pathophysiology of human obesity 98
Prevalence of Hyperandrogenic States in Late Adolescent and Young Women: Epidemiological Survey on Italian High-School Students 96
Improving the diagnosis of 11β-hydroxylase deficiency using home-made MLPA probes: identification of a novel chimeric CYP11B2/CYP11B1 gene in a Sicilian patient 96
null 96
Sindrome dell'ovaio policistico e diabete di tipo 2 94
Hirsutism and virilization 94
High serum concentration of total inhibin in polycystic ovary syndrome 93
Quality of diet, screened by the Mediterranean diet quality index and the evaluation of the content of advanced glycation endproducts, in a population of high school students from Emilia Romagna 90
Insulin-sensitizing agents in women with polycystic ovary syndrome. 90
Metabolic alterations and cardiovascular risk factors in the polycystic ovary syndrome. 88
Insulin-sensitizing agents in polycystic ovary syndrome. 87
Liraglutide and cardiovascular outcomes in type 2 diabetes 86
Type 2 diabetes and the polycystic ovary syndrome. 86
null 85
MANAGEMENT OF ENDOCRINE DISEASE: Secondary polycystic ovary syndrome: theoretical and practical aspects. 85
Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors 85
Mechanisms and treatment of obesity in polycystic ovary syndrome 84
Molecular and phenotypical characterization of 10 families with 11ß-hydroxylase deficiency 83
The role of low-grade inflammation in the polycystic ovary syndrome. 81
Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. 80
Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age. 79
Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome 78
European survey of diagnosis and management of the polycystic ovary syndrome: Results of the ESE PCOS Special Interest Group's Questionnaire 78
null 77
Response of the hypothalamic-pituitary-adrenal axis to small dose arginine-vasopressin and daily urinary free cortisol before and after alprazolam pre-treatment differs in obesity. 76
Involvement of the endocannabinoid system in metabolism and fertility 75
Mitochondrial oxidative phosphorylation is impaired in patients with congenital lipodystrophy. 75
New perspectives on the definition and management of polycystic ovary syndrome 75
Biomediators in polycystic ovary syndrome and cardiovascular risk 73
Glucose intolerance states in women with the polycystic ovary syndrome. 70
Insulin resistance, obesity and the metabolic syndrome in polycystic ovary syndrome. 69
Steroid reference intervals in women: influence of menopause, age and metabolism 69
null 68
European lipodystrophy registry: Background and structure 68
The impact of obesity on reproduction in women with polycystic ovary syndrome. 66
Obesity and infertility 66
Functional effects of polymorphisms in the human gene encoding 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1): a sequence variant at the translation start of 11 beta-HSD1 alters enzyme levels. 66
Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE) 65
Nutrition and polycistic ovary syndrome 64
Cytokine Profile in Striated Muscle Laminopathies: New Promising Biomarkers for Disease Prediction 64
Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions 60
Totale 10.636
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.009
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.009
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.870 0 0 0 0 0 283 363 382 367 180 121 174
2020/20211.592 309 108 49 86 30 142 35 108 157 90 74 404
2021/20221.999 161 57 119 132 193 94 71 165 73 134 478 322
2022/20232.170 233 295 93 305 148 131 69 114 350 165 158 109
2023/2024728 77 116 54 48 54 114 53 48 16 77 48 23
2024/20251.422 108 445 272 185 412 0 0 0 0 0 0 0
Totale 11.558